


Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:



wherein:

A is phenyl or 3-6 membered cycloalkyl; each of which is optionally substituted with --C₁₋₆alkyl, cyano, -C₁₋₄aminoalkyl, -C₁₋₄alkoxyl, -C₁₋₆haloalkyl, -C₁₋₄haloalkoxyl, and halo;

L is -C₁₋₆alkylene-;

each R¹ is independently selected from -C₁₋₆alkyl, cyano, -C₁₋₄aminoalkyl, -C₁₋₄alkoxyl, -C₁₋₆haloalkyl, -C₁₋₄haloalkoxyl, and halo;

each R² is H or -C₁₋₆alkyl;

R³ is selected from -C₁₋₆alkyl, -CN, -C₁₋₄alkoxyl, -C₁₋₆haloalkyl, -C₁₋₄haloalkoxyl, halogen, -C(O)R^{3a}, -C(O)OR^{3b}, -C(O)NR^{3c}R^{3d}, -P(O)R^{3e}R^{3f}, -P(O)(OR^{3g})(OR^{3h}), -P(O)(OR³ⁱ)(R^{3j}), -S(O)₂R^{3k}, -S(O)₂NR^{3l}R^{3m}, -S(O)R³ⁿ, -NR^{3o}R^{3p}, -NR^{3q}C(O)R^{3r}, -N(R^{3s})C(O)OR^{3t} and -NR^{3u}S(O)₂R^{3v}, wherein each of the -C₁₋₆alkyl, -C₁₋₄alkoxyl, -C₁₋₆haloalkyl, and -C₁₋₄haloalkoxyl is independently optionally substituted by hydroxyl, -NR^{3w}R^{3x}, -C₁₋₄alkoxyl, -S(O)₂NR^{3y}R^{3z}, or -S(O)₂R^{3a2}; wherein each of R^{3w}, R^{3x}, R^{3y}, and R^{3z} is independently H, -C₁₋₄alkyl or -C₁₋₆haloalkyl and R^{3a2} is -C₁₋₄alkyl or -C₁₋₆haloalkyl, or

any two R³ may combine with one atom to form a 5-6 membered fused heterocycloalkyl, wherein the heterocycloalkyl comprises one or two heteroatoms selected from N and S, and wherein the heterocycloalkyl is independently optionally substituted with one or two groups selected from -C₁₋₆alkyl, -C₁₋₄aminoalkyl -CN, -C₁₋₄alkoxyl, halogen, -C₁₋₆haloalkyl and -C₁₋₄haloalkoxyl;

each of R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R³ⁱ, R^{3j}, R^{3k}, R³ⁿ, R^{3o}, R^{3p}, R^{3q}, R^{3r}, R^{3s}, R^{3t}, R^{3u}, R^{3v} is independently selected from H, -C₁₋₆alkyl and -C₁₋₆haloalkyl;

each of R^{3l} and R^{3m} is independently selected from H, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -aminoalkyl, and -hydroxyalkyl, wherein the -C₁₋₆alkyl is optionally further substituted by 3-6


membered cycloalkyl, and wherein the 3-6 membered cycloalkyl substituent is optionally further substituted by 1-2 halo; or R^{23} and R^{24} may combine with the N to form a 5-6 membered heterocycloalkyl, wherein the 5-6 membered heterocycloalkyl optionally further comprises one hetero atom selected from S and N;

p is 1, 2 or 3;


q is 0 or 1; and

each of n and m is independently selected from 0, 1 and 2.

2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein p is 1.
3. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein p is 2.
4. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein p is 3.
5. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein q is 0.
6. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein q is 1.
7. A compound of formula (IA), or a pharmaceutically acceptable salt thereof:




8. A compound of formula (IB), or a pharmaceutically acceptable salt thereof:



9. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^2 is H or CH_3 .
10. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein L is selected from $-\text{CH}_2-$, $-\text{CH}(\text{CH}_3)-$, $-\text{CH}_2\text{CH}_2-$ and $-\text{CH}_2\text{CH}_2\text{CH}_2-$.
11. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R^3 is $-\text{S}(\text{O})_2\text{NH}_2$, $-\text{S}(\text{O})_2\text{N}(\text{CH}_3)_2$, $-\text{S}(\text{O})_2\text{NHCH}_3$, $-\text{S}(\text{O})_2\text{NHCH}_2-$

cyclobutyl, $-\text{S}(\text{O})_2\text{NH}-\text{CH}_2\text{-cyclopentyl}$, $-\text{S}(\text{O})_2\text{NH}-\text{CH}_2\text{-cyclohexyl}$, $-\text{S}(\text{O})_2\text{NH}-\text{CH}_2\text{-difluorocyclobutyl}$, $-\text{S}(\text{O})_2\text{CH}_3$ and $-\text{S}(\text{O})_2\text{CHF}_2$.

12. The compound of claim 1, having formula (IC), or a pharmaceutically acceptable salt thereof:



wherein R^4 is selected from $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{NHCH}_3$, $-\text{NH}-\text{CH}_2\text{-cyclobutyl}$, $-\text{NH}-\text{CH}_2\text{-cyclopentyl}$, $-\text{NH}-\text{CH}_2\text{-cyclohexyl}$, $-\text{NH}-\text{CH}_2\text{-difluorocyclobutyl}$, $-\text{CH}_3$ and $-\text{CHF}_2$ or is combined with R^3 to form a 1,1-dioxido-2,3-dihydrothiophenyl or 1,1-dioxido-2,3-dihydroisothiazolyl ring.

13. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A is phenyl, optionally substituted with F or Cl.

14. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein A is selected from cyclobutyl, cyclopentyl, cyclohexyl and bicyclo[1.1.1]pentanyl, each of which is optionally substituted with F or Cl.

15. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^{1a} and R^{1b} are independently selected from $-\text{H}$, $-\text{CH}_3$ and $-\text{CH}_2\text{CH}_3$.

16. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^3 is H, $-\text{OCH}_3$ or $-\text{OCH}_2\text{CH}_3$.

17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of Examples 1-127.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any of the preceding claims, and a pharmaceutically acceptable carrier or excipient.

19. The pharmaceutical composition of claim 18 further comprising at least one additional pharmaceutical agent.

20. The pharmaceutical composition of claim 19 wherein the at least one additional pharmaceutical agent is selected from the group consisting of interferons, ribavirin and ribavirin analogs, cyclophilin binder, HCV NS3 protease inhibitors, HCV NS5a inhibitors, P7 inhibitor, entry inhibitor, NS4b inhibitor, alpha-glucosidase inhibitors, host protease inhibitors, immune modulators, symptomatic relief agents, nucleoside and non-nucleoside NS5b inhibitors.

21. A method for treating a disease caused by a viral infection comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-17.
22. The method of claim 21 wherein the viral infection is caused by a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
23. The method of claim 22 wherein said viral infection is caused by dengue virus.
24. The compound of any one of the claims 1-17 for use as a medicament.
25. The use of a compound of any one of claims 1 to 17 in the manufacture of a medicament for treating a disease caused by a viral infection.
26. The use of claim 25 wherein the viral infection is caused by a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
27. The use of claim 26 wherein the viral infection is caused by dengue virus.